<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019796</url>
  </required_header>
  <id_info>
    <org_study_id>0112001154 DEP2014-52930-R</org_study_id>
    <nct_id>NCT03019796</nct_id>
  </id_info>
  <brief_title>Exercise Training Effects on Metabolic Syndrome: Interactions With Medication</brief_title>
  <acronym>METSYND</acronym>
  <official_title>Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Ministry of Economy and Competitiveness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Castilla-La Mancha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the effects of different exercise training modalities (continuous, intervallic,
      and resistance training) on cardiorespiratory and metabolic fitness of metabolic syndrome
      patients when this training interacts with their habitual medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity,
      the effects of different modalities of exercise training on cardiorespiratory and metabolic
      fitness. The main objective is to weight the effects of exercise training separately and in
      conjunction with the subject's habitual pharmacological treatment to identify the best
      combination of drug and exercise.

      Methods and design: Randomized, pretest-posttest control group experimental design. Project
      developed in a single center with the collaboration of the regional public health system.

      Subjects: Will be referred by their primary care physicians to our study unit. Up to 160
      subjects all of them with metabolic syndrome will be recruited (20% women).

      Measurements:

        1. Specifically, the investigators, will study cardiovascular adaptations that increase, i)
           maximal aerobic capacity measured by VO2max, ii) anaerobic and respiratory compensation
           point ventilatory thresholds, iii) cardiac function measured by assessing cardiac output
           and stroke volume using the re-breathing technique, iv) arterial stiffness, measured by
           pulse wave velocity and augmentation index using applanation tonometry (SphygmoCor
           System), v) central and peripheral blood pressure, and vi) biological markers of
           endothelial dysfunction using reactive hyperemia with a laser Doppler fluxmeter in
           central and peripheral blood vessels.

        2. The metabolic adaptations under study will include, i) insulin resistance measured by
           IVGTT, ii) fat oxidation by indirect calorimetry, iii) intramuscular proteins involved
           in energetics by percutaneous muscle biopsy and western blots, iv) mitochondria
           biogenesis by activity of citrate synthase and v) stable-isotopic study of glucose and
           free fatty acids kinetics in blood (using gas-chromatography mass-spectrometry
           analysis).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery systolic and diastolic pressures.</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by using a ECG-gated automated sphygmomanometer (Tango, Suntec Medical, NC., US).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist perimeter.</measure>
    <time_frame>6 months</time_frame>
    <description>Using calibrated measurement tape at the iliac crest level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting blood level of glucose, cholesterol HDL, triglycerides, glycosylated hemoglobin and protein C reactive.</measure>
    <time_frame>6 months</time_frame>
    <description>Blood lipid profile to detect metabolic syndrome (Alberti et al., Circulation, 2009)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen consumption rate during exercise (VO2max).</measure>
    <time_frame>6 months</time_frame>
    <description>Index of cardiorespiratory fitness assessed during an incremental cycle-ergometer test using an indirect calorimetry system (AEI, Moxus system, US).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaerobic threshold (AT) and respiratory compensation point (RCP).</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by changes in ratios between pulmonary ventilation rates and oxygen and carbon dioxide production during the incremental cycle-ergometer test (Wasserman et al., 2005).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal rate of fat oxidation.</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated in grams per min during the incremental cycloergometer test wih the use of indirect calorimetry system (AIE, Moxus system, US).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness by pulse wave velocity (PWV) and augmentation index (AI).</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by applanation tonometry in the radial and femoral arteries (SphygmoCor; AtCor Medical; Sydney, Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral post-occlusion reactive hyperemia.</measure>
    <time_frame>6 months</time_frame>
    <description>Index of endothelial function assessed by measuring forearm peak flow after occlusion using a laser Doppler fluxmeter probe (DRT4; Moor Instruments, Axminster, UK).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity using intravenous glucose tolerance test (IVGTT).</measure>
    <time_frame>6 months</time_frame>
    <description>Infusion of a glucose bolus and blood sampling for the analysis of glucose and insulin following the procedures described by Tura et al., (Diabetologia, 2010)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat.</measure>
    <time_frame>6 months</time_frame>
    <description>Determined by dual-energy X-ray absorptiometry (Hologic Serie Discovery Wi QDR, Bedford, US).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rates of appearance, dissapearance of glycerol and palmitate in blood.</measure>
    <time_frame>6 months</time_frame>
    <description>Infusion of stable isotope of 13C palmitate and measurement of enrichment in blood of 12/13C palmitate using gas chromatography-mass spectrometry (Hewlett Packard 5971).</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of oxidation of plasma and intracellular free fatty acids.</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of enrichment of 13CO2 collected in expired air using isotope ratio-mass spectrometry (IRMS).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Exercise Therapy</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Cardiorespiratory Fitness</condition>
  <arm_group>
    <arm_group_label>NO EXERCISE TRAINING</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants of this arm will remain physically inactive (i.e., less than 1 day a week of exercise) during the 4 months of intervention.
The investigators will withhold their medication during 48 h to achieve 2 conditions:
no exercise, no medication.
no exercise, yes medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXERCISE TRAINING</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants of this arm will exercise during 4 months (i.e., 3 days a week during 45-60 min) at workloads individualized by percent heart rate of either continuous or intervallic aerobic exercise, with increases in workload as exercise adaptations manifest during training.
The investigators will withhold their habitual medication during 48 h to achieve the following 2 conditions:
c) yes exercise, no medication d) yes exercise, yes medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EXERCISE TRAINING</intervention_name>
    <description>EXERCISE TRAINING AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).</description>
    <arm_group_label>EXERCISE TRAINING</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>NO EXERCISE TRAINING</intervention_name>
    <description>REMAINING INACTIVE AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).</description>
    <arm_group_label>NO EXERCISE TRAINING</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic syndrome patients diagnosed according to the International diabetes
             federation consensus of 2009 (Alberti, et al., Circulation).

          -  18-65 years old

        Exclusion Criteria:

        Cardiovascular disease or musculo-skeletal that prevents them from being able to perform
        intense exercise.

          -  Respiratory failure

          -  Patient ends

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Castilla-La Mancha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Castilla-La Mancha (Exercise Physiology Lab)</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
      <phone>92526800</phone>
      <phone_ext>5515</phone_ext>
      <email>ricardo.mora@uclm.es</email>
    </contact>
    <contact_backup>
      <last_name>Juan F Ortega, MD, PhD</last_name>
      <phone>+3492526800</phone>
      <phone_ext>5515</phone_ext>
      <email>juanfernando.ortega@uclm.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan F Ortega, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Mora-Rodriguez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Pallares JG, Mora-Rodriguez R. Cardiovascular Drift during Training for Fitness in Patients with Metabolic Syndrome. Med Sci Sports Exerc. 2017 Mar;49(3):518-526. doi: 10.1249/MSS.0000000000001139.</citation>
    <PMID>27787335</PMID>
  </reference>
  <reference>
    <citation>Ortega JF, Morales-Palomo F, Fernandez-Elias V, Hamouti N, Bernardo FJ, Martin-Doimeadios RC, Nelson RK, Horowitz JF, Mora-Rodriguez R. Dietary supplementation with omega-3 fatty acids and oleate enhances exercise training effects in patients with metabolic syndrome. Obesity (Silver Spring). 2016 Aug;24(8):1704-11. doi: 10.1002/oby.21552. Epub 2016 Jun 29.</citation>
    <PMID>27356240</PMID>
  </reference>
  <reference>
    <citation>Mora-Rodriguez R, Ortega JF, Guio de Prada V, Fernández-Elías VE, Hamouti N, Morales-Palomo F, Martinez-Vizcaino V, Nelson RK. Effects of Simultaneous or Sequential Weight Loss Diet and Aerobic Interval Training on Metabolic Syndrome. Int J Sports Med. 2016 Apr;37(4):274-81. doi: 10.1055/s-0035-1564259. Epub 2015 Dec 14.</citation>
    <PMID>26667921</PMID>
  </reference>
  <reference>
    <citation>Ortega JF, Fernández-Elías VE, Hamouti N, Pallares JG, Mora-Rodriguez R. Higher Insulin-sensitizing Response after Sprint Interval Compared to Continuous Exercise. Int J Sports Med. 2015 Mar 26. [Epub ahead of print]</citation>
    <PMID>25811624</PMID>
  </reference>
  <reference>
    <citation>Martínez-Vizcaíno V, Sánchez-López M, Notario-Pacheco B, Salcedo-Aguilar F, Solera-Martínez M, Franquelo-Morales P, López-Martínez S, García-Prieto JC, Arias-Palencia N, Torrijos-Niño C, Mora-Rodríguez R, Rodríguez-Artalejo F. Gender differences on effectiveness of a school-based physical activity intervention for reducing cardiometabolic risk: a cluster randomized trial. Int J Behav Nutr Phys Act. 2014 Dec 10;11:154. doi: 10.1186/s12966-014-0154-4.</citation>
    <PMID>25491026</PMID>
  </reference>
  <reference>
    <citation>Ortega JF, Fernández-Elías VE, Hamouti N, Pallarés JG, Mora-Rodriguez R. Higher insulin-sensitizing response after sprint interval compared to continuous exercise. Int J Sports Med. 2015 Mar;36(3):209-14. doi: 10.1055/s-0034-1389942. Epub 2014 Nov 6.</citation>
    <PMID>25376729</PMID>
  </reference>
  <reference>
    <citation>Ortega JF, Hamouti N, Fernández-Elías VE, Mora-Rodriguez R. Comparison of glucose tolerance tests to detect the insulin sensitizing effects of a bout of continuous exercise. Appl Physiol Nutr Metab. 2014 Jul;39(7):787-92. doi: 10.1139/apnm-2013-0507. Epub 2014 Apr 11.</citation>
    <PMID>24971679</PMID>
  </reference>
  <reference>
    <citation>Ortega JF, Hamouti N, Fernández-Elías VE, de Prada MV, Martínez-Vizcaíno V, Mora-Rodríguez R. Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance. Acta Diabetol. 2014 Oct;51(5):749-55. doi: 10.1007/s00592-014-0580-4. Epub 2014 Mar 29.</citation>
    <PMID>24682492</PMID>
  </reference>
  <reference>
    <citation>Mora-Rodriguez R, Ortega JF, Hamouti N, Fernandez-Elias VE, Cañete Garcia-Prieto J, Guadalupe-Grau A, Saborido A, Martin-Garcia M, Guio de Prada V, Ara I, Martinez-Vizcaino V. Time-course effects of aerobic interval training and detraining in patients with metabolic syndrome. Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):792-8. doi: 10.1016/j.numecd.2014.01.011. Epub 2014 Jan 29.</citation>
    <PMID>24656853</PMID>
  </reference>
  <reference>
    <citation>Díez-Fernández A, Sánchez-López M, Mora-Rodríguez R, Notario-Pacheco B, Torrijos-Niño C, Martínez-Vizcaíno V. Obesity as a mediator of the influence of cardiorespiratory fitness on cardiometabolic risk: a mediation analysis. Diabetes Care. 2014;37(3):855-62. doi: 10.2337/dc13-0416. Epub 2013 Nov 6.</citation>
    <PMID>24198304</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2016</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>May 6, 2017</last_update_submitted>
  <last_update_submitted_qc>May 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

